Latham Represents Gossamer Bio, Inc. in Exchange Offer and Consent Solicitation Transaction to Eliminate Over US$120 Million of Debt With Existing Noteholder Support

Gossamer Bio, Inc. (NASDAQ: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, has announced that it has commenced an exchange offer to exchange any and all of its 5.00% convertible senior notes due 2027 for a pro rata portion of (i) up to US$72 million in aggregate principal amount of its new 7.50% convertible senior secured first lien notes due 2030, (ii) up to 317,647,058 shares of its common stock or, in lieu of issuing shares of common stock to the extent such shares would cause any eligible holder to beneficially own greater than 9.99% of the outstanding common stock, prefunded warrants to purchase shares of common stock, and (iii) with respect to eligible holders who tender prior to the Early Tender Date, warrants to purchase shares of common stock.

Latham & Watkins LLP represents Gossamer Bio, Inc. in the transaction with a Capital Markets team led by partners Matt Bush, Greg Rodgers, Ryan Gold, and Kevin Reyes, with associates Nadia Patino, Connor Adams, Shelby Harrison, Gavin Tan, Justin Deuell, and assistance from Olivia Wagner. Advice was also provided on restructuring and special situations matters by partners Andrew Parlen and George Klidonas, with associate Kenny Hildebrand; on finance matters by partner Seniz Yakut, with associates Donna Hope and Linda Xu, and assistance from Jolena Sun; on compensation and benefits matters by partner Holly Bauer, with associate Julie Voorhes; on intellectual property matters by partner Steve Chinowsky; and on tax matters by partner Aaron Bernstein, with associate Farrah Yan.